Peptide Antibiotics Market

Peptide Antibiotics Market Overview (2022 to 2032)

The global peptide antibiotics market was valued at around US$ 4.4 Billion at the end of 2021. The market is projected to register a 6.6% CAGR and top a valuation of US$ 8.3 Billion by 2032.

The market for peptide antibiotics is likely to thrive in the future given the rising incidence of disorders such as bloodstream infections, hospital-acquired infections, and bacterial skin infections.

Peptide antibiotics are peptides having strong antibacterial and antifungal properties. Peptide antibiotics are an essential part of the innate immune system, which living organisms rely on as their first line of defense against invading pathogens. The primary sites for the synthesis of these peptides are tissues that have direct environmental contact, such as the skin, gut, and lungs.

Peptide antibiotics are anti-infective and anti-tumor medicines that contain polypeptide chains. Peptide antibiotics come in two varieties: ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. The advantages of peptide antibiotics include high specificity, high efficacy, and low toxicity.

Attributes	Details
Peptide Antibiotics Market Value in 2021	US$ 4.4 Billion
Peptide Antibiotics Market Value in 2032	US$ 8.3 Billion
Peptide Antibiotics Market CAGR (2022 to 2032)	6.6%

What are the Major Drivers Boosting the Demand for Peptide Antibiotics Market?

In light of factors like rising peptide antibiotic research & development activity and a high number of product approvals, the market is anticipated to experience potential growth. Additionally, the potential for side effects from traditional antibiotics and the rise in occurrences of antimicrobial resistance are anticipated to fuel the market throughout the forecast period.

Over the projected period, rising rates of cancer and other related infections are expected to spur growth. Some peptide antibiotics are prescribed to treat malignancies such as Hodgkin's lymphoma and a few different kinds of skin cancers. Globocan 2020 reports that there were 83,087 instances of Hodgkin's lymphoma and 5,44,352 cases of non-Hodgkin lymphoma. Due to doctor recommendations, it is anticipated that the effectiveness of various existing products would result in higher sales. BLEOMYCIN for injection is a combination of cytotoxic glycopeptide antibiotics, which is derived from the bacterium Streptomyces verticillus. It is utilized for the treatment of testicular cancer, squamous cell carcinoma, and other types of lymphomas.

Which Region Shows Strong Growth Potential in the Peptide Antibiotics Market?

The peptide antibiotics market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

The largest market for peptide antibiotics is in North America. Increased Research and Development activities in the region are anticipated to fuel the market over the projected period due to the region's increased demand for antibiotics.

The European peptide antibiotics industry is likewise anticipated to experience profitable expansion. Some of the important drivers of growth are the existence of major manufacturers and strategic initiatives undertaken by prominent companies.

The East Asian region is predicted to show lucrative growth owing to increasing rates of infectious disease and the vast presence of the elderly population.

Who are the Key Players in the Peptide Antibiotics Market?

Pfizer Inc., Merck & Co., Inc., AbbVie Inc, GSK Group of Companies, Sandoz International GmbH, Xellia Pharmaceuticals, AuroMedics Pharma LLC, Theravance Biopharma, Novartis, GlaxoSmithKline, Eli Lilly.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 6.6% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Billion, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered	Product, Disease, Route of Administration, Distribution Channel, Region
Region Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa
Key Countries Profiled	USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Players	Pfizer Inc.; Merck & Co., Inc.; AbbVie Inc; GSK Group of Companies; Sandoz International GmbH; Xellia Pharmaceuticals; AuroMedics Pharma LLC; Theravance Biopharma; Novartis; GlaxoSmithKline; Eli Lilly
Customization	Available Upon Request

Key Segments Covered in the Peptide Antibiotics Market Report

By Product:

• Ribosomal Synthesized Peptide Antibiotics
• Non-Ribosomal Synthesized Peptide Antibiotics

By Disease:

• Skin Infection
• HABP/VABP
• Blood Stream Infection
• Others

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)